Quest Diagnostics had its Relative Strength (RS) Rating upgraded from 88 to 91 Friday.
This unique rating identifies market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the trailing 52 weeks matches up against all other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains typically have an RS Rating of above 80 at the beginning of a new climb.
Here Are 3 Keys For Successful Stock Investing
While the stock is not near an ideal entry right now, see if it is able to form and break out from a proper base.
In terms of top and bottom line numbers, Quest Diagnostics has posted rising EPS growth in each of the last three reports. Revenue growth has also moved higher over the same time frame. Quest Diagnostics is expected to release its next quarterly numbers on or around Apr. 22.
Quest Diagnostics holds the No. 3 rank among its peers in the Medical-Services industry group. Option Care Health is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
